Biogen research chief says misinformation is cause for controversy surrounding newly approved Alzheimer s drug
Dr Alfred Sandrock, head of research and development at Biogen, published a letter combatting misinformation surrounding its drug, Aduhelm
He says that debate over whether the drug works is normal after FDA accelerated approval
Cleveland Clinic and Mount Sinai both said they will not administer the controversial drug to patients
Aduhelm received FDA approval last month despite little evidence that it worked in clinical trials
Drug will cost an individual $56,000 for a year of treatment, and could cost Medicare as much as $29 billion a year
Biogen accused of over-marketing controversial new Alzheimer's drug
dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
Two Major Health Systems Will Not Administer Controversial Aduhelm
neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.
Filed to:aducanumab
alzheimers diseasebiogenclinical trialfederal assistance in the united statesfood and drug administrationhealth medical pharmahealthcare reform in the united statesjanet woodcockkaiser family foundationkatie porterlife sciencesmedicaidmedicarepresidency of lyndon b johnsonsam gandythe centers for medicare and medicaid services
Photo: Matthew Simmons, Getty Images
Parts of the medical world are continuing to rebel against Aduhelm, the controversial treatment developed by Biogen and recently approved for Alzheimer’s disease by the U.S. Food and Drug Administration. This week, two major medical centres in the U.S. said that they would not treat their patients with the drug.
The Cleveland Clinic, as first reported by the New York Times yesterday, assembled a formal panel of experts to review the evidence behind aducanumab, the active ingredient of Aduhelm, before coming to their decision.
Mass General Brigham unlikely to recommend Alzheimer’s drug to patients on blood thinners Jonathan Saltzman © Provided by The Boston Globe More than a third of patients who took Aduhelm in clinical trials had small brain bleeds or an accumulation of fluid detected by MRI.
Mass General Brigham is unlikely to offer Biogen’s controversial new Alzheimer’s drug to patients taking blood thinners because of concerns about the risk of bleeding in the brain, according to two doctors helping to develop a policy on the medicine for the state’s largest health care provider.
Dr. Teresa Gomez-Isla and Dr. Kirk Daffner, Alzheimer’s specialists at Massachusetts General Hospital and Brigham and Women’s Hospital, respectively, noted that patients on anticoagulant medications were excluded from clinical trials of the recently approved Aduhelm. The Cambridge biotech’s medicine was associated with “microhemorrhages,” or small amounts of bleeding, in the brains o